Fidelity Emerging Markets Multifactor ETF (BATS: FDEV)

Latest news for Fidelity Emerging Markets Multifactor ETF (BATS:FDEV)

Healthcare

Financial Services

Consumer Defensive

Industrials

Communication Services

Consumer Cyclical

Real Estate

Utilities

Technology

Energy

Basic Materials

Other

The fund invests at least 80% of its assets in securities included in the index and in depository receipts representing securities included in the index. The index is designed to reflect the performance of stocks of large- and mid-capitalization developed international companies that have attractive valuations, high quality profiles, positive momentum signals, lower volatility than the broader developed international equity market, and lower correlation to the U.S. equity market.

Novo Nordisk A/S Class B

Astrazeneca Plc

Roche Holding Ag

Bkw Ag

Redeia Corporacion Sa

Snam Spa

Fidelity International Multifactor ETF

Long Ideas

Broad U.S. Equity ETFs

New ETFs

Emerging Market ETFs

Trading Ideas

ETFs

FENY

FSMD

FDEV

FDEM

Fidelity Adds 3 ETFs To Factor Lineup

Fidelity Emerging Markets Multifactor ETF

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.

News

STXS

Stereotaxis' Genesis Robotic System Debuts in Finland, Treats First Patients

Deutsche Bank analyst Omotayo Okusanya initiates coverage on EastGroup Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGP#NYSE">EGP</a>) with a Buy rating and announces Price Target of $180.

Price Target

Initiation

Analyst Ratings

Deutsche Bank Initiates Coverage On EastGroup Props with Buy Rating, Announces Price Target of $180

D. Boral Capital analyst Jason Kolbert maintains Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) with a Buy and maintains $6 price target.

ARTL

D. Boral Capital Maintains Buy on Artelo Biosciences, Maintains $6 Price Target

Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced that it has secured $33 million in funding. This funding positions the company to accelerate its growth and deliver on its mission to proliferate industrial autonomous vehicles.

Cyngn Secures $33M Funding to Advance Industrial Autonomous Vehicle Technology

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) with a Buy and maintains $10 price target.

ANIX

D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target

Smartkem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>), which is seeking to change the world of electronics using its disruptive organic thin-film transistors (OTFTs), recapped its key accomplishments for 2024 and set its goals 2025.
 Smartkem Chairman and Chief Executive Officer, Ian Jenks commented, "2024 was a pivotal year for Smartkem. In December, we raised $7.65 million and, together with our collaboration partner, were awarded a $1.1 million grant for a project to develop the world's first rollable, transparent microLED display. We uplisted to Nasdaq, increasing trading liquidity and broadening access to investors. We made significant strides in our plans to commercialize our proprietary semiconductor materials with strategic partnerships and collaborations with industry-leaders. We believe we have strengthened our position as a key player in the market for microLED displays, as well as packaging solutions for advanced computing and AI chips and CMOS for smart sensors. Looking toward 2025, we are focused on achieving qualifications and design wins with existing and new collaborations. We believe our technology will help drive adoption of advanced display and other technologies, with the microLED industry projected to grow from $150 million in 2024 to over $4 billion by 2031.

SMTK

Smartkem Recaps 2024 Milestones, Eyes 2025 Growth in Rollable MicroLED Displays and AI Chip Solutions

Full year 2024 revenue is now expected in the range of $710 to $720 million. Full year 2024 GAAP diluted earnings per share is expected in the range of $1.07 to $1.26, while Non-GAAP diluted earnings per share is expected in the range of $1.69 to $1.76.

VECO

Veeco Updates Q4 Guidance: Projects Revenues Of $175M-$185M Vs. $182.98M Estimate (Prior View: $165M-$185M); Company Sees Adjusted EPS $0.36-$0.44 Vs. $0.46 Estimate (Prior View: $0.35-$0.45)

<ul>
<li>This collaboration is part of SolarEdge's domestic manufacturing plans that have already created ~1,750 new jobs in Tampa, Florida, and Austin, Texas</li>
</ul>

SEDG

SolarEdge And Summit Ridge Energy Partner To Advance U.S. Solar Adoption With Domestically Manufactured Technology

SIG: -21% &#x7C; <a href="https://www.benzinga.com//node/42969440">Signet Jewelers shares are trading lower after the company reported a drop in total same store sales for the holiday season and lowered its Q4 guidance.</a>
&nbsp;
APLD: 38% &#x7C; <a href="https://www.benzinga.com//node/42970143">Applied Digital Secures $5B Financing Facility With Macquarie Asset Management to Expand Ellendale HPC Campus and Repay Debt</a>
&nbsp;
RGNX: 29% &#x7C; <a href="https://www.benzinga.com//node/42967838">REGENXBIO Partners with Nippon Shinyaku in $810M Deal for Hunter and Hurler Syndrome Therapies</a>

Movers

APLD

RGNX

Market-Moving News for January 14th

B of A Securities analyst Steve Byrne upgrades Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) from Neutral to Buy and lowers the price target from $48 to $40.

Upgrades

B of A Securities Upgrades Olin to Buy, Lowers Price Target to $40

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) with a Buy and maintains $18 price target.

Reiteration

TNYA

HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target

<a href="https://www.globenewswire.com/Tracker?data=-qLsGcxU_aSbLTHmBTDruiZB8m_yjjxjkZSQ_mNulOYkxYUTR5t5e7bjgQbzRAVBjh2CB71sxHrd2k5R5_Qj6HD0uHFRNOHqBUNo_ffkPr4=">Kymera Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced its corporate goals for 2025, including anticipated progress on its clinical pipeline of immunology programs.
"We expect 2025 to be another year of significant progress and accomplishments, and likely our busiest year to date. After unveiling our broader immunology strategy and new pipeline last year, we are poised to demonstrate the clinical potential of our first-in-class, wholly owned STAT6 and TYK2 oral degrader programs," said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. "Our vision is to leverage the power of targeted protein degradation to deliver, for the first time in industry, oral drugs with biologics-like activity that have the potential to revolutionize the treatment of many inflammatory diseases with significant unmet needs. We are rapidly progressing the development of our first-in-industry oral STAT6 degrader, KT-621, and will have Phase 1 healthy volunteer data, Phase 1b atopic dermatitis data, as well as initiate the first Phase 2b study, all in 2025."

KYMR

Kymera Therapeutics Targets 2025 Milestones with STAT6 and TYK2 Oral Degrader Programs for Immunology

2024 Highlights
<ul>
<li>2024 attributable gold production of 667,000 ounces achieving the mid-point of the Company's 2024 production guidance which was increased mid-year. Both Essakane and Westwood achieved the top end of their production estimates.</li>
<li>Cash costs and AISC for Essakane and Westwood are expected to be towards the lower end of the 2024 guidance ranges of $1,175 and $1,275 per ounce sold and $1,700 and $1,825 per ounce sold. The guidance was lowered mid-year following the strong production achieved during the first half of 2024 at both assets.</li>
<li>Record revenues expected with annual gold sales of 654,000 ounces on an attributable basis at an average realized gold price of approximately $2,326 per ounce.</li>
<li>IAMGOLD to report year-end financial results on February 20, 2025, after market close.</li>
</ul>
2025 Outlook
<ul>
<li>Attributable gold production of 735,000 to 820,000 ounces, driven by the ramp-up of Côté Gold to nameplate production later in the year and continued strong production levels from Essakane and Westwood.</li>
<li>Cash cost guidance of $1,200 to $1,350 per ounce sold and AISC guidance of $1,625 to $1,800 per ounce sold. Costs are expected to be lower in the second half of the year as Côté progresses towards nameplate throughput.</li>
</ul>

Guidance

IAMGOLD Delivers 2024 Production Of 667,000 Ounces, Projects Up To 820,000 Ounces Of Gold Production In 2025

Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>, "Ocular", the "Company"))), a biopharmaceutical company committed to redefining the retina experience, outlined exceptional clinical progress across its registrational program for AXPAXLI&#x2122; in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic retinopathy (NPDR), and the Company's strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference (JPM 2025).

OCUL

Ocular Therapeutix Showcases Progress on AXPAXLI for Wet AMD and Diabetic Retinopathy at JPM 2025

Market-Moving Exclusives

Exclusives

SNGX

EXCLUSIVE: Soligenix Tells Benzinga 'Patients have responded positively to HyBryte therapy, with over 70% (5 of the 6 subjects who have completed at least 18 weeks of therapy) already achieving "Treatment Success'

EXCLUSIVE: Soligenix Tells Benzinga 'Study Supported by $2.6 Million FDA Orphan Products Development Grant'

On Tuesday, Soligenix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL), a type of cancer that starts in the T-lymphocytes, a type of white blood cell that fights infection.
Cutaneous T-cell lymphoma&nbsp;is a group&nbsp;of rare blood cancers&nbsp;that affects the skin.
Nine patients have been enrolled and treated with HyBryte over up to 54 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41968331/soligenix-kickstarts-dusquetide-mid-stage-study-for-patients-with-inflamed-blood-vessels" rel="noreferrer noopener">Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels</a>
Patients have responded positively to HyBryte therapy, with over 70% (5 of the 6 subjects who have completed at least 18 weeks of therapy) already achieving "Treatment Success."
Treatment Success is predefined in the study's protocol as a greater than or equal to 50% improvement in the cumulative mCAILS (modified Composite Assessment of Index Lesion Severity) score compared to the baseline.
Three of the five Treatment Successes were achieved within the first 12 weeks of treatment, with two patients achieving a "complete response" by 18 weeks.
Of the remaining patients, two have recently started the study, and two had to drop out for logistical reasons. One showed a substantial improvement (&gt;30%) by their Week 18 visit. In addition, HyBryte appears to be safe and well-tolerated in all patients.
In December, Soligenix announced that patient enrollment had opened for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for CTCL.
The confirmatory Phase 3 study, FLASH2, builds on the previous statistically significant Phase 3 (FLASH) study, as well as a recent comparative study (HPN-CTCL-04) and an ongoing investigator-initiated study, each further supporting the design of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42505309/exclusive-soligenix-starts-confirmatory-late-stage-trial-for-hybryte-for-type-of-blood-cancer" rel="noreferrer noopener">the FLASH2 clinical trial</a>.
The active ingredient in HyBryte is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later.
Price Action: SNGX stock closed at $3.13 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say" target="_blank" rel="noreferrer noopener">Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts</a></li>
</ul>

Biotech

Health Care

General

EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year

EXCLUSIVE: Soligenix Tells Benzinga HyBryte Expanded Treatment Continues To Demonstrate Outcomes In -Early-Stage Cutaneous T-Cell Lymphoma

Preliminary Fourth Quarter and Full Year 2024 Updates (based on unaudited financial information)
<ul>
<li>BRIUMVI U.S. net product revenue expected to be $103.6 million and $310 million for the fourth quarter and full year of 2024, respectively</li>
<li>Year-end 2024 cash position of approximately $310 million</li>
</ul>
Preliminary selected financial information presented in this release are unaudited, subject to financial closing procedures and adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results planned to occur before March 3, 2025. &nbsp;
2025 Target Guidance
<ul>
<li>Full Year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million</li>
<li>Full year 2025 target operating expense of approximately $300 million &nbsp;</li>
</ul>
2025 Development Pipeline Anticipated Milestones
<ul>
<li>Commence pivotal program of subcutaneous BRIUMVI</li>
<li>Commence pivotal programs to consolidate the Day 1 and Day 15 dose of BRIUMVI, and to evaluate 30 minute BRIUMVI maintenance infusions</li>
<li>Enroll participants into the ongoing trial evaluating BRIUMVI in autoimmune diseases outside of Multiple Sclerosis (MS)</li>
<li>Enroll participants into the Phase 1 azer-cel trial in autoimmune disease, beginning with primary progressive MS</li>
<li>Present updated data at major medical conferences throughout the year</li>
</ul>

TGTX

TG Therapeutics Expects Q4 BRIUMVI US Net Product Revenue Of $103.6M, FY24 RIUMVI US Net Product Revenue Of $310M, FY25 Total Revenue Of $540M

Toronto Dominion Says TD Asset Management Inc. Broadens Its ETF Lineup With Two New U.S. Dollar Offerings And Expanded Suite Of Target Maturity Bond ETFs

Fidelity International Multifactor ETF declares quarterly distribution of $0.2150

Fidelity International Multifactor ETF declares quarterly distribution of $0.2740

2024 Midyear Investment Directions

Weekly Market Pulse: The Fed Declares Victory

Chart Of The Week: Dollar Index Moving Lower

Fidelity International Multifactor ETF declares $0.195 dividend

Will International Stocks Outperform Again?

Fidelity International Multifactor ETF declares quarterly distribution of $0.1350

Comments

Fidelity Emerging Markets Multifactor ETF

News

Latest news for Fidelity Emerging Markets Multifactor ETF (BATS:FDEV)

Friday, March 01, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga